Skip to main content


Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice

Fig. 2

Food intake (a) and body weight gain (b) in lean and ob/ob−/− with and without treatment at baseline and during empagliflozin treatment. Data were analyzed using Anova with Tukey’s multiple comparisons test and are presented as mean with standard deviation. *p < 0.05 and **p < 0.01 for 5 and 10 weeks compared with baseline, and p ≤ 0.05 for ob/ob−/− treated vs. untreated group

Back to article page